Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?Zacks Investment Research • 09/03/25
Halozyme Therapeutics, Inc. (HALO) Hit a 52 Week High, Can the Run Continue?Zacks Investment Research • 09/03/25
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is BrightZacks Investment Research • 08/08/25
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTSPRNewsWire • 08/05/25
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • 07/29/25
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple MyelomaPRNewsWire • 07/23/25
Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates AgainZacks Investment Research • 07/22/25
Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade)Seeking Alpha • 07/14/25
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)PRNewsWire • 06/20/25
Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?Zacks Investment Research • 06/05/25
4 Stocks With Strong Interest Coverage Ratios to Buy in June 2025Zacks Investment Research • 06/03/25
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)Zacks Investment Research • 05/28/25
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor IndicationsPRNewsWire • 05/28/25